Case Study

Accelerating GLP-1 Drug Development: How Metsera, Certara & Altasciences Reached Phase 2

See how Metsera, Certara, and Altasciences built an integrated MIDD partnership to advance GLP-1 programs…

CertaraNovember 12, 2026

Poster

Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy

Explore how QSP modeling informs T-cell engager dose selection for autoimmune diseases, balancing efficacy and…

Piet van der GraafOctober 26, 2026

Live Events

Certara Biotech Forum London: Building an Investor-Ready Strategy and Story

–

CertaraOctober 19, 2026

Conference

2nd Model-Informed Drug Development Summit

–

sarah CarrOctober 13, 2026

Webinar

From Data to Decisions: Getting More from Clinical Trial Evidence

Matt Zierhut, PhD MBAOctober 13, 2026

On-Demand Webinar

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human

Watch the webinar to learn how QSP and a model-informed target product profile guide indication,…

Danielle PillsburyOctober 9, 2026

Publication

Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

Explore population PK modeling of dolutegravir in plasma and cerebrospinal fluid to characterize CNS penetration…

CertaraOctober 5, 2026

Publication

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma

Explore a simultaneous population PK/PD model characterizing the dynamic relationships between belantamab mafodotin, sBCMA, and…

CertaraOctober 5, 2026

Conference

2nd TCE for Autoimmune Disease Summit

–

Danielle PillsburyOctober 5, 2026

Webinar

How Do You Know You Have the Right Dose? Using Exposure-Response Evidence to Justify and Defend Dose Decisions

Danielle PillsburyOctober 1, 2026

Certara Services